Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

And Novo Nordisk is asking the U.S. Food and Drug Administration (FDA) to bar compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight ...

Shares in Novo Nordisk A/S (DK:NOVO.B) have lost a fifth of their market value since the end of June, the point at which the Danish pharma group revealed that it was committing around $4bn (£3.2bn) to ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's (NVO) semaglutide and Eli Lilly's (LLY) tirzepatide could also be effective in tackling Alzheimer's disease. The study was ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s ...

Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic ...

Novo Nordisk A/S (NYSE:NVO) has established itself as a leader in the rapidly growing market for diabetes and obesity treatments, with its GLP-1 receptor agonists Ozempic and Wegovy driving ...